Abstract:Objectives:As a zinc-dependent proteinase family member, A Disintegrin and Metalloproteinase 9 (ADAM9) has the metalloproteinase domain that performs proteolytic function to liberate or shed factors, such as bFGF, VEGF, EGF, TGF-α and IGF, from cell surface and make them more accessible to tumor cells. It was shown in previous studies that the upregulation of ADAM9 in breast cancer is associated with metastasis.In this study, we examined the effect of ADAM9 on the cell proliferation, migration and invasion and elucidated the molecular mechanism in TNBC. We hypothesize that ADAM9 sheds Tumor Necrosis Factor alpha (TNF-α), which activates TNF receptor and then triggers PI3K-dependent NF-kappa B pathway, affecting metastatic phenotypes of triple negative breast cancer (TNBC).Materials and Methods:Correlation of the levels of ADAM9 expression and survival time in triple negative breast cancer patients was analysed by the Kaplan-Meier (KM) plotter integrative data analysis tool. The TNBC subjects were divided into two groups of high and low ADAM9 expression levels with respect to the median. We also compared the protein expression levels of ADAM9 in a highly aggressive, invasive and poorly differentiated TNBC cell line, MDA-MB-231, and a non-tumorigenic epithelial cell line, MCF-10A.ADAM9 was knocked down in MDA-MB-231 using siRNA. In comparison to negative and blank controls, we examined the cell proliferation, migration and invasion, and the phosphorylation levels of AKT subject to ADAM9 knockdown. We also profiled the mRNA expression levels of ADAM9 and NF-kappa B in breast cancer patients.Results:As shown in Figure 1(a), the survival curves of these two groups were plotted and compared using Kaplan-Meier survival analysis, indicating that lower ADAM9 expression is linked to better survival rate (p=0.0038). Figure 1(b) illustrates significantly higher ADAM9 protein level in MDA-MB-231, compared with MCF-10A (p=0.0019).It is shown in Figure 2 and Figure 3(a) that the cell proliferation, migration and invasion, and the phosphorylation of AKT are significantly suppressed by ADAM9 knockdown in the aggressive TNBC cell line. Figure 3(b) shows significant association between ADAM9 and NF-kappa B in the mRNA expression level (p<0.001).Conclusions:The results clearly showed the activation of PI3K-dependent NF-kappa B pathway triggered by ADAM9. This suggests a novel molecular mechanism that the stable homotrimers of TNF-α are released from the membrane through the proteolytic cleavage by ADAM9 and activate the signaling pathway leading to metastatic phenotype of TNBC.Acknowledgments:This project was supported by the National Basic Research Program of China (973 program, 2014CB744505).1Citation Format: Rui Zhou, Hong Zhang, Chi Shing Cho, Sze Chuen Wong, Mei Tian, Wing Chi Chan. The role of ADAM9 and PI3K-dependent NF-kappa B pathway in promoting metastasis of triple-negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1116.

Epigenetic Silencing of ADAMTS18 Promotes Cell Migration and Invasion of Breast Cancer Through AKT and NF‐κB Signaling

Inactivation Of Adamts18 By Aberrant Promoter Hypermethylation Contribute To Lung Cancer Progression

The Metalloprotease ADAMTS8 Displays Antitumor Properties Through Antagonizing EGFR–MEK–ERK Signaling and is Silenced in Carcinomas by CpG Methylation

ADAM17 Promotes Epithelial-Mesenchymal Transition Via TGF-β/Smad Pathway in Gastric Carcinoma Cells

The 3p14.2 Tumour Suppressor ADAMTS9 is Inactivated by Promoter CpG Methylation and Inhibits Tumour Cell Growth in Breast Cancer.

The expression of ADAMTS14 is regulated by promoter DNA methylation and is associated with poor prognosis in colorectal cancer

ADAMTS9 is Silenced by Epigenetic Disruption in Colorectal Cancer and Inhibits Cell Growth and Metastasis by Regulating Akt/p53 Signaling

Hypermethylation Of The 16q23.1 Tumor Suppressor Gene Adamts18 In Clear Cell Renal Cell Carcinoma

Methylation Status of ADAM12 Promoter Are Associated with Its Expression Levels in Colorectal Cancer.

Abstract 1116: the Role of ADAM9 and PI3K-dependent NF-kappa B Pathway in Promoting Metastasis of Triple-Negative Breast Cancer

ADAMTS18 deficiency associates extracellular matrix dysfunction with a higher risk of HER2-positive mammary tumorigenesis and metastasis

ADAM9 Mediates Triple-Negative Breast Cancer Progression Via AKT/NF-κB Pathway.

ADAMTS8 Inhibits Cell Proliferation and Invasion, and Induces Apoptosis in Breast Cancer

Breast Cancer Cells Induce Stromal Fibroblasts To Secrete Adamts1 For Cancer Invasion Through An Epigenetic Change

ADAMTS16 drives epithelial-mesenchymal transition and metastasis through a feedback loop upon TGF-β1 activation in lung adenocarcinoma

Epigenetic silencing of ADAMTS5 is associated with increased invasiveness and poor survival in patients with colorectal cancer

ADAM17 promotes colorectal cancer migration and invasion by regulating the TGF-β/Smad signaling pathway

TET1 Suppresses Cancer Invasion by Activating the Tissue Inhibitors of Metalloproteinases.

Adiponectin As A Potential Tumor Suppressor Inhibiting Epithelial-To-Mesenchymal Transition but Frequently Silenced in Prostate Cancer by Promoter Methylation

ADAMTS9-AS1 Constrains Breast Cancer Cell Invasion and Proliferation Via Sequestering Mir-301B-3p.

MP45-14 EPIGENETIC REGULATION OF CANDIDATE TUMOR SUPPRESSOR GENE ADAMTS18 IN HUMAN BLADDER CANCER ASSOCIATED WITH ITS PROGNOSIS